Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119178 · ClinicalTrials.gov registry record
EX-PRESS® P-50 and EX-PRESS® P-200
A clinical trial, sponsored by Alcon Research.
- Completed
- Registry status
- 122
- Enrollment target
NCT06119178: Completed study, sponsored by Alcon Research.
NCT06119178 is a clinical trial that has completed, run by Alcon Research. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06119178 has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term clinical performance and safety outcomes for EX-PRESS Glaucoma Filtration Devices Models P-50 and P-200.
Primary Outcome
IOP will be measured for each eye individually using applanation tonometry and recorded in millimeters mercury (mmHG).
Interventions
- DEVICE EX-PRESS P-50 filtration device
- DEVICE EX-PRESS P-200 filtration device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2024-06-20 |
What the finished NCT06119178 record still lists
NCT06119178 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which EX-PRESS P-50 filtration device is the first listed.
NCT06119178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06119178 about?
NCT06119178 is a clinical study titled "EX-PRESS® P-50 and EX-PRESS® P-200". The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term clinical performance and safety outcomes for EX-PRESS Glaucoma Filtration Devices Models P-50 and P-200.
What is the current status of trial NCT06119178?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2023-11-21. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT06119178?
The interventions under investigation include: EX-PRESS P-50 filtration device (DEVICE), EX-PRESS P-200 filtration device (DEVICE).
Who is sponsoring clinical trial NCT06119178?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI